Top

Journal of Cardiovascular Translational Research

Published in:

03-05-2022 | Arterial Occlusive Disease | Original Article

LncRNA HDAC11-AS1 Suppresses Atherosclerosis by Inhibiting HDAC11-Mediated Adropin Histone Deacetylation

Authors: Liang Li, Wei Xie

Published in: Journal of Cardiovascular Translational Research | Issue 6/2022

Abstract

LncRNA HDAC11-AS1 (HDAC11-AS1) is the natural antisense transcript of HDAC11, a key enzyme for DNA histone deacetylation. We evaluated the role of HDAC11-AS1 in atherosclerosis. In this research, we found that HDAC11-AS1 ameliorated blood lipid levels and atherosclerosis in high fat-dieted apoE^−/− mice by regulating HDAC11 negatively. The change in blood lipid levels is related to the expression of LPL, which is enhanced by HDAC11-AS1 through regulating adropin histone deacetylation in vitro and in vivo. In conclusion, HDAC11-AS1 plays an anti-atherogenic role through adropin to induce LPL expressions, thereby enhancing TG metabolism. The results are valuable for the further development of HDAC11-AS1 and its clinical applications. It provides a new clinical therapeutic target for cardiovascular disease treatment.

Khan, S. S., Ning, H., Wilkins, J. T., Allen, N., Carnethon, M., Berry, J. D., et al. (2018). Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiology, 3, 280–287. https://doi.org/10.1001/jamacardio.2018.0022.CrossRef

Rahman, M. S., & Woollard, K. (2017). Atherosclerosis. Advances in Experimental Medicine and Biology, 1003, 121–144. https://doi.org/10.1007/978-3-319-57613-8_7CrossRef

Ayyappa, K. A., Shatwan, I., Bodhini, D., Bramwell, L. R., Ramya, K., Sudha, V., Anjana, R. M., Lovegrove, J. A., Mohan, V., Radha, V., & Vimaleswaran, K. S. (2017). High fat diet modifies the association of lipoprotein lipase gene polymorphism with high density lipoprotein cholesterol in an Asian Indian population. Nutrition & Metabolism (London), 14, 8. https://doi.org/10.1186/s12986-016-0155-1CrossRef

Nakajima, K., Tokita, Y., Sakamaki, K., Shimomura, Y., Kobayashi, J., Kamachi, K., Tanaka, A., Stanhope, K. L., Havel, P. J., Wang, T., Machida, T., & Murakami, M. (2017). Triglyceride content in remnant lipoproteins is significantly increased after food intake and is associated with plasma lipoprotein lipase. Clinica Chimica Acta, 465, 45–52. https://doi.org/10.1016/j.cca.2016.12.011CrossRef

Takahashi, S. (2017). Triglyceride rich lipoprotein -LPL-VLDL receptor and Lp(a)-VLDL receptor pathways for macrophage foam cell formation. Journal of Atherosclerosis and Thrombosis, 24, 552–559. https://doi.org/10.5551/jat.RV17004CrossRef

Olivecrona, G., & Olivecrona, T. (2010). Triglyceride lipases and atherosclerosis. Current Opinion in Lipidology, 21, 409–415. https://doi.org/10.1097/MOL.0b013e32833ded83CrossRef

Shapiro, M. D., & Fazio, S. (2016). From lipids to inflammation: New approaches to reducing atherosclerotic risk. Circulation Research, 118, 732–749. https://doi.org/10.1161/CIRCRESAHA.115.306471CrossRef

Larsson, M., Allan, C. M., Jung, R. S., Heizer, P. J., Beigneux, A. P., Young, S. G., & Fong, L. G. (2017). Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL. Journal of Lipid Research, 58, 1893–1902. https://doi.org/10.1194/jlr.M078220CrossRef

Lian, A., Wu, K., Liu, T., Jiang, N., & Jiang, Q. (2016). Adropin induction of lipoprotein lipase expression in tilapia hepatocytes. Journal of Molecular Endocrinology, 56, 11–22. https://doi.org/10.1530/JME-15-0207CrossRef

10.

Ghoshal, S., Stevens, J. R., Billon, C., Girardet, C., Sitaula, S., Leon, A. S., et al. (2018). Adropin: An endocrine link between the biological clock and cholesterol homeostasis. Molecular Metabolism, 8, 51–64. https://doi.org/10.1016/j.molmet.2017.12.002.CrossRef

11.

Yosaee, S., Soltani, S., Sekhavati, E., & Jazayeri, S. (2016). Adropin- a novel biomarker of heart disease: A systematic review article. Iranian Journal of Public Health, 45, 1568–1576.

12.

Li, L., Xie, W., Zheng, X. L., Yin, W. D., & Tang, C. K. (2016). A novel peptide adropin in cardiovascular diseases. Clinica Chimica Acta, 453, 107–113. https://doi.org/10.1016/j.cca.2015.12.010CrossRef

13.

Lovren, F., Pan, Y., Quan, A., Singh, K. K., Shukla, P. C., Gupta, M., Al-Omran, M., Teoh, H., & Verma, S. (2010). Adropin is a novel regulator of endothelial function. Circulation, 122, S185–S192. https://doi.org/10.1161/CIRCULATIONAHA.109.931782CrossRef

14.

Bousmpoula, A., Kouskouni, E., Benidis, E., Demeridou, S., Kapeta-Kourkouli, R., Chasiakou, A., & Baka, S. (2018). Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: Correlation with lipoprotein lipid profiles. Gynecological Endocrinology, 34, 153–156. https://doi.org/10.1080/09513590.2017.1379498CrossRef

15.

Sato, K., Yamashita, T., Shirai, R., Shibata, K., Okano, T., Yamaguchi M., Mori, Y. Hirano T., & Watanabe T. (2018). Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. International Journal of Molecular Sciences, 19(5). https://doi.org/10.3390/ijms19051293

16.

Stoll, S., Wang, C., & Qiu, H. (2018). DNA methylation and histone modification in hypertension. International Journal of Molecular Sciences, 19(4). https://doi.org/10.3390/ijms19041174

17.

von Knethen, A., & Brune, B. (2019). Histone deacetylation inhibitors as therapy concept in sepsis. International Journal of Molecular Sciences, 20(2). https://doi.org/10.3390/ijms20020346

18.

Watts, B. R., Wittmann, S., Wery, M., Gautier, C., Kus, K., Birot, A., Heo, D. H., Kilchert, C., Morillon, A., & Vasiljeva, L. (2018). Histone deacetylation promotes transcriptional silencing at facultative heterochromatin. Nucleic Acids Research, 46, 5426–5440. https://doi.org/10.1093/nar/gky232CrossRef

19.

Bassett, S. A., & Barnett, M. P. (2014). The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients, 6, 4273–4301. https://doi.org/10.3390/nu6104273CrossRef

20.

Sagarkar, S., Balasubramanian, N., Mishra, S., Choudhary, A. G., Kokare, D. M., & Sakharkar, A. J. (2019). Repeated mild traumatic brain injury causes persistent changes in histone deacetylase function in hippocampus: Implications in learning and memory deficits in rats. Brain Research, 1711, 183–192. https://doi.org/10.1016/j.brainres.2019.01.022CrossRef

21.

Zheng, X. X., Zhou, T., Wang, X. A., Tong, X. H., & Ding, J. W. (2015). Histone deacetylases and atherosclerosis. Atherosclerosis, 240, 355–366. https://doi.org/10.1016/j.atherosclerosis.2014.12.048CrossRef

22.

Sahakian, E., Powers, J. J., Chen, J., Deng, S. L., Cheng, F., Distler, A., Woods, D. M., Rock-Klotz, J., Sodre, A. L., Youn, J. I., Woan, K. V., Villagra, A., Gabrilovich, D., Sotomayor, E. M., & Pinilla-Ibarz, J. (2015). Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Molecular Immunology, 63, 579–585. https://doi.org/10.1016/j.molimm.2014.08.002CrossRef

23.

Stammler, D., Eigenbrod, T., Menz, S., Frick, J. S., Sweet, M. J., Shakespear, M. R., Jantsch, J., Siegert, I., Wolfle, S., Langer, J. D., Oehme, I., Schaefer, L., Fischer, A., Knievel, J., Heeg, K., Dalpke, A. H., & Bode, K. A. (2015). Inhibition of histone deacetylases permits lipopolysaccharide-mediated secretion of bioactive IL-1beta via a caspase-1-independent mechanism. The Journal of Immunology, 195, 5421–5431. https://doi.org/10.4049/jimmunol.1501195CrossRef

24.

Byun, S. K., An, T. H., Son, M. J., Lee, D. S., Kang, H. S., Lee, E. W., Han, B. S., Kim, W. K., Bae, K. H., Oh, K. J., & Lee, S. C. (2017). HDAC11 inhibits myoblast differentiation through repression of MyoD-dependent transcription. Molecules and Cells, 40, 667–676. https://doi.org/10.14348/molcells.2017.0116CrossRef

25.

Wang, X., Wu, Y., Jiao, J., & Huang, Q. (2018). Mycobacterium tuberculosis infection induces IL-10 gene expression by disturbing histone deacetylase 6 and histonedeacetylase 11 equilibrium in macrophages. Tuberculosis (Edinburgh, Scotland), 108, 118–123. https://doi.org/10.1016/j.tube.2017.11.008CrossRef

26.

Sun, L., Marin de Evsikova, C., Bian, K., Achille, A., Telles, E., Pei, H., & Seto, E. (2018). Programming and regulation of metabolic homeostasis by HDAC11. eBioMedicine, 33, 157–168. https://doi.org/10.1016/j.ebiom.2018.06.025CrossRef

27.

Gil, N., & Ulitsky, I. (2020). Regulation of gene expression by cis-acting long non-coding RNAs. Nature Reviews Genetics, 21, 102–117. https://doi.org/10.1038/s41576-019-0184-5CrossRef

28.

Cai, Y., Yang, Y., Chen, X., Wu, G., Zhang, X., Liu, Y., Yu, J., Wang, X., Fu, J., Li, C., Jose, P. A., Zeng, C., & Zhou, L. (2016). Circulating “lncRNA OTTHUMT00000387022” from monocytes as a novel biomarker for coronary artery disease. Cardiovascular Research, 112, 714–724. https://doi.org/10.1093/cvr/cvw022CrossRef

29.

Zhen, Z., Ren, S., Ji, H., Ding, X., Zou, P., & Lu, J. (2019). The lncRNA DAPK-IT1 regulates cholesterol metabolism and inflammatory response in macrophages and promotes atherogenesis. Biochemical and Biophysical Research Communications, 516, 1234–1241. https://doi.org/10.1016/j.bbrc.2019.06.113CrossRef

30.

Shang, P., Chen, G., Zu, G., Song, X., Jiao, P., You, G., Zhao, J., Li, H., & Zhou, H. (2019). Long noncoding RNA expression analysis reveals the regulatory effects of nitinol-based nanotubular coatings on human coronary artery endothelial cells. International Journal of Nanomedicine, 14, 3297–3309. https://doi.org/10.2147/IJN.S204067CrossRef

31.

Jung, J., Lee, S., Cho, H. S., Park, K., Ryu, J. W., Jung, M., Kim, J., Kim, H., & Kim, D. S. (2019). Bioinformatic analysis of regulation of natural antisense transcripts by transposable elements in human mRNA. Genomics, 111, 159–166. https://doi.org/10.1016/j.ygeno.2018.01.011CrossRef

32.

Zhao, X., Li, J., Lian, B., Gu, H., Li, Y., & Qi, Y. (2018). Global identification of Arabidopsis lncRNAs reveals the regulation of MAF4 by a natural antisense RNA. Nature Communications, 9, 5056. https://doi.org/10.1038/s41467-018-07500-7CrossRef

33.

Jadaliha, M., Gholamalamdari, O., Tang, W., Zhang, Y., Petracovici, A., Hao, Q., Tariq, A., Kim, T. G., Holton, S. E., Singh, D. K., Li, X. L., Freier, S. M., Ambs, S., Bhargava, R., Lal, A., Prasanth, S. G., Ma, J., & Prasanth, K. V. (2018). A natural antisense lncRNA controls breast cancer progression by promoting tumor suppressor gene mRNA stability. PLoS Genetics, 14, e1007802. https://doi.org/10.1371/journal.pgen.1007802CrossRef

34.

Bodary, P. F., Gu, S., Shen, Y., Hasty, A. H., Buckler, J. M., & Eitzman, D. T. (2005). Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, e119–e122. https://doi.org/10.1161/01.ATV.0000173306.47722.ecCrossRef

35.

Feng, Z., Hai-ning, Y., Xiao-man, C., Zun-chen, W., Sheng-rong, S., & Das, U. N. (2014). Effect of yellow capsicum extract on proliferation and differentiation of 3T3-L1 preadipocytes. Nutrition, 30, 319–325. https://doi.org/10.1016/j.nut.2013.08.003CrossRef

36.

Kim, D. Y., Kim, M. S., Sa, B. K., Kim, M. B., & Hwang, J. K. (2012). Boesenbergia pandurata attenuates diet-induced obesity by activating AMP-activated protein kinase and regulating lipid metabolism. International Journal of Molecular Sciences, 13, 994–1005. https://doi.org/10.3390/ijms13010994CrossRef

37.

Ewart, M. A., & Kennedy, S. (2012). Diabetic cardiovascular disease–AMP-activated protein kinase (AMPK) as a therapeutic target. Cardiovascular & Hematological Agents in Medicinal Chemistry, 10, 190–211. https://doi.org/10.2174/187152512802651015CrossRef

38.

Rodrigues, S. C., Pantaleao, L. C., Nogueira, T. C., Gomes, P. R., Albuquerque, G. G., Nachbar, R. T., Torres-Leal, F. L., Caperuto, L. C., Lellis-Santos, C., Anhe, G. F., & Bordin, S. (2014). Selective regulation of hepatic lipid metabolism by the AMP-activated protein kinase pathway in late-pregnant rats. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 307, R1146–R1156. https://doi.org/10.1152/ajpregu.00513.2013CrossRef

39.

Knoll, M., Lodish, H. F., & Sun, L. (2015). Long non-coding RNAs as regulators of the endocrine system. Nature Reviews Endocrinology, 11, 151–160. https://doi.org/10.1038/nrendo.2014.229CrossRef

40.

He, W., Liang, B., Wang, C., Li, S., Zhao, Y., Huang, Q., Liu, Z., Yao, Z., Wu, Q., Liao, W., Zhang, S., Liu, Y., Xiang, Y., Liu, J., & Shi, M. (2019). MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene, 38, 4637–4654. https://doi.org/10.1038/s41388-019-0747-0CrossRef

41.

Zhao, X. Y., Xiong, X., Liu, T., Mi, L., Peng, X., Rui, C., Guo, L., Li, S., Li, X., & Lin, J. D. (2018). Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis. Nature Communications, 9, 2986. https://doi.org/10.1038/s41467-018-05383-2CrossRef

42.

Scheideler, M. (2019). Regulatory Small and Long Noncoding RNAs in Brite/Brown Adipose Tissue. Handbook of Experimental Pharmacology, 251, 215–237. https://doi.org/10.1007/164_2018_123CrossRef

43.

Zhang, H. N., Xu, Q. Q., Thakur, A., Alfred, M. O., Chakraborty, M., Ghosh, A., & Yu, X. B. (2018). Endothelial dysfunction in diabetes and hypertension: Role of microRNAs and long non-coding RNAs. Life Sciences, 213, 258–268. https://doi.org/10.1016/j.lfs.2018.10.028CrossRef

44.

Wu, G., Cai, J., Han, Y., Chen, J., Huang, Z. P., Chen, C., Cai, Y., Huang, H., Yang, Y., Liu, Y., Xu, Z., He, D., Zhang, X., Hu, X., Pinello, L., Zhong, D., He, F., Yuan, G. C., Wang, D. Z., & Zeng, C. (2014). LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation, 130, 1452–1465. https://doi.org/10.1161/CIRCULATIONAHA.114.011675CrossRef

45.

Huang, P., Huang, F. Z., Liu, H. Z., Zhang, T. Y., Yang, M. S., & Sun, C. Z. (2019). LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism, 94, 1–8. https://doi.org/10.1016/j.metabol.2019.01.018CrossRef

46.

Bagchi, R. A., Ferguson, B. S., Stratton, M. S., Hu, T., Cavasin, M. A., Sun, L., Lin, Y. H., Liu, D., Londono, P., Song, K., Pino, M. F. Sparks, L. M., Smith, S. R., Scherer, P. E., Collins, S., Seto, E., & McKinsey, T. A. (2018). HDAC11 suppresses the thermogenic program of adipose tissue via BRD2. JCI Insight, 3(15). https://doi.org/10.1172/jci.insight.120159

47.

Bhaskara, S. (2018). Histone deacetylase 11 as a key regulator of metabolism and obesity. eBioMedicine, 35, 27–28. https://doi.org/10.1016/j.ebiom.2018.08.008CrossRef

48.

Fan, X. D., Wan, L. L., Duan, M., & Lu, S. (2018). HDAC11 deletion reduces fructose-induced cardiac dyslipidemia, apoptosis and inflammation by attenuating oxidative stress injury. Biochemical and Biophysical Research Communications, 503, 444–451. https://doi.org/10.1016/j.bbrc.2018.04.090CrossRef

49.

Butler, A. A., Tam, C. S., Stanhope, K. L., Wolfe, B. M., Ali, M. R., O’Keeffe, M., St-Onge, M. P., Ravussin, E., & Havel, P. J. (2012). Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. Journal of Clinical Endocrinology and Metabolism, 97, 3783–3791. https://doi.org/10.1210/jc.2012-2194CrossRef

50.

Ganesh Kumar, K., Zhang, J., Gao, S., Rossi, J., McGuinness, O. P., Halem, H. H., Culler, M. D., Mynatt, R. L., & Butler, A. A. (2012). Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring), 20, 1394–1402. https://doi.org/10.1038/oby.2012.31CrossRef

Title: LncRNA HDAC11-AS1 Suppresses Atherosclerosis by Inhibiting HDAC11-Mediated Adropin Histone Deacetylation
Authors: Liang Li
Wei Xie
Publication date: 03-05-2022
Publisher: Springer US
Keyword: Arterial Occlusive Disease
Published in: Journal of Cardiovascular Translational Research / Issue 6/2022
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-022-10248-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

LncRNA HDAC11-AS1 Suppresses Atherosclerosis by Inhibiting HDAC11-Mediated Adropin Histone Deacetylation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2022

Calcitriol Supplementation Protects Against Apoptosis and Alleviates the Severity of Abdominal Aortic Aneurysm Induced by Angiotensin II and Anti-TGFβ

The Role of the Association Between Serum C-Reactive Protein Levels and Coronary Plaque Macrophage Accumulation in Predicting Clinical Events — Results from the CLIMA Registry

Pentraxin 3 in Circulating Microvesicles: a Potential Biomarker for Acute Heart Failure After Cardiac Surgery with Cardiopulmonary Bypass

Cardiac Electrophysiological Changes and Downregulated Connexin 43 Prompts Reperfusion Arrhythmias Induced by Hypothermic Ischemia–Reperfusion Injury in Isolated Rat Hearts

Analogue Mean Systemic Filling Pressure: a New Volume Management Approach During Percutaneous Left Ventricular Assist Device Therapy

Fasudil Ameliorates Osteoporosis Following Myocardial Infarction by Regulating Cardiac Calcitonin Secretion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page